at://
/
app.bsky.feed.post
/
3mmwwvv5l622d
sign in
All
4
Record
2
Post
1
PostEmbed
1
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
Good efficacy for challenging disease + improved QoL in pall setting. #lymsm www.asco.org/abstracts-pr...
18d
www.asco.org
Fixed-duration subcutaneous (SC) mosunetuzumab (Mosun) in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Interim analysis and patient-reported outcomes (PROs) ...
Ajay Major, MD, MBA
